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Abstract: Friedreich’s ataxia (FA) is a severe disorder with autosomal recessive inheritance that
is caused by the abnormal expansion of GAA repeat in intron 1 of FRDA gen. This alteration
leads to a partial silencing of frataxin transcription, causing a multisystem disorder disease that
includes neurological and non-neurological damage. Recent studies have proven the effectiveness of
neurotrophic factors in a number of neurodegenerative diseases. Therefore, we intend to determine if
liver growth factor (LGF), which has a demonstrated antioxidant and neuroprotective capability, could
be a useful therapy for FA. To investigate the potential therapeutic activity of LGF we used transgenic
mice of the FXNtm1MknTg (FXN)YG8Pook strain. In these mice, intraperitoneal administration
of LGF (1.6 µg/mouse) exerted a neuroprotective effect on neurons of the lumbar spinal cord and
improved cardiac hypertrophy. Both events could be the consequence of the increment in frataxin
expression induced by LGF in spinal cord (1.34-fold) and heart (1.2-fold). LGF also upregulated
by 2.6-fold mitochondrial chain complex IV expression in spinal cord, while in skeletal muscle it
reduced the relation oxidized glutathione/reduced glutathione. Since LGF partially restores motor
coordination, we propose LGF as a novel factor that may be useful in the treatment of FA.
Keywords: liver growth factor; Friedreich’s ataxia; neuroprotection; oxidative stress; frataxin
1. Introduction
Cerebellar ataxias (CA) include a group of diseases characterized by a lack of motor coordination
mainly related with dysfunction of the cerebellum and associated neuronal circuits. Friedreich ataxia
(FA) is a severe disorder with autosomal recessive inheritance that is caused by the abnormal
expansion of GAA repeat in intron 1 of FRDA gen. This alteration leads to a partial silencing of
transcription of frataxin (FXN), its encoded protein, causing a multisystem disorder disease that
includes neurological damage, mainly spinocerebellar ataxia, and non-neurological signs such as
hypertrophic cardiomyopathy and diabetes Mellitus type 2. The degree of reduction in FXN expression
tightly correlates with the severity of the disease [1,2]. Although FXN’s exact function remains
unknown, available evidence supports a role in iron metabolism. The major cellular consequences of
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its deficiency include: impairment of iron-sulfur clusters biogenesis, altered cellular iron metabolism
with cytosolic iron depletion and mitochondrial iron accumulation, increased oxidative stress, and
mitochondrial dysfunction [3,4]. Several therapeutic strategies have expanded rapidly over recent
years [5]. Because the success of these therapies for FA is limited [6], there is a need to search for
new molecules with beneficial effects on damaged organs in order to ameliorate the quality of life of
FA patients.
Liver growth factor (LGF) is a 64 kDa molecule purified in 1986 by Díaz-Gil and colleagues from
the plasma of partially hepactomized rats [7]. They demonstrated that LGF is an albumin–bilirubin
complex, the concentration of which is nearly undetectable in sera from healthy humans or rats, but
dramatically increases in the presence of hepatobiliary disorders or liver injury [8,9]. Recent studies
show that LGF is a pleiotropic factor capable of stimulating cell proliferation, and tissue regeneration
in hepatic and extrahepatic pathologies [10–14]. The use of LGF as a neural tissue regenerator has been
recently protected (Patent No US 2014/8,642,551 B2) [15]. The administration of LGF stimulates the
sprouting of DA terminals in the striatum of hemiparkinsonian rats [16–18], stimulates the generation
of new neurons, and promotes their migration in this experimental model of Parkinson’s disease [17],
and its delivery into the brain stimulates the survival of grafted fetal neural stem cells and their
differentiation to an endothelial-like phenotype [19].
Several studies revealed that LGF modulates the functional homeostasis through its
anti-inflammatory and antioxidant action. Thus, in spontaneously hypertensive rats (SHR) LGF
improved nitric oxide availability through the reduction of superoxide anion levels, and normalized the
plasmatic levels of several oxidative stress markers [20]. LGF also exerted a considerable antioxidant
activity in vitro due to its effectiveness as a scavenger of several reactive oxygen species involved
in cardiovascular disorders [21]. In addition, this factor reduced the expression of proinflammatory
proteins in hemiparkinsonian rats [16] and protected calbindin-positive terminals from 3-acetylpiridine
neurotoxicity by reducing the extracellular glutamate concentration and the activation of microglia in
the cerebellum [22].
Considering the antioxidant activity of LGF [20,21], as well as the positive effects produced by
the factor in a rat model of CA [22], we decided to analyze the therapeutic properties of this growth
factor in an FA experimental model [transgenic mice of the FXNtm1MknTg (FXN) YG8Pook strain].
The results showed that peripheral administration of LGF exerts a neuroprotective effect on sensory
neurons located in the lumbar spinal cord and reduced cardiac hypertrophy. Both events may be
due to increased expression of FXN promoted by the factor in the spinal cord and the heart, since
neurodegeneration in both structures is directly related to the protein deficiency. Interestingly, LGF
stimulates AKT phosphorylation in the spinal cord, and increases Bcl2/Bax ratio in the brain stem and
cerebellum. Furthermore, LGF also reduced oxidative stress in skeletal muscle and improved motor
coordination in this experimental model of FA.
2. Results
2.1. Liver Growth Factor (LGF) Ameliorates Motor Coordination in YG8R Mice
The effects of LGF IP treatment on motor abilities and coordination were studied using the Rota
Rod test. As shown in Figure 1A, the motor performance of wild-type (WT) mice showed a progressive
impairment that reached a plateau between seven and eight months of age. By contrast, in YG8R and
YG8R+LGF mice motor performance was stable between five and eight months of age, and significantly
reduced at six to seven months, as compared with WT mice (Figure 1A).
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Figure 1. Liver growth factor (LGF) treatment partially restores motor coordination in YG8R mice. 
(A) Shows the time (in seconds) spent on the rotating rod at increasing acceleration of the three 
groups of animals observed, demonstrating that under this demanding rotarod condition no 
beneficial effect of LGF is detected; In (B) the % of times that mice stay on the rotating rod for 3 min at 
constant speed (4 rpm) in the WT (white circles), YG8R (black circles), or YG8R+LGF (grey circles) 
mice. Note the poorer performance of YG8R versus WT mice of five to seven months, and that 
shortly after treatment values are significantly higher in the LGF-treated than in the vehicle-treated 
YG8R mice. Results are the mean ± Standard Error of Mean (SEM) of 6–8 independent animals.  
++ p < 0.01, +++ p < 0.001 vs. YG8R; * p < 0.05, ** p < 0.01 vs. WT; # p < 0.05, ## p < 0.01 vs. YG8R+LGF. 
When we analyzed motor performance at constant speed (4 rpm), we observed that at five to 
seven months of age the percentage of times that YG8R mice stayed for three minutes in rotarod was 
lower than in WT mice (Figure 1B). At seven to eight months, YG8R+LGF mice showed a significant 
increase in this parameter, as compared with YG8R mice (Figure 2B), suggesting that LGF treatment 
improved motor coordination in these mice. 
2.2. LGF Prevents Neuronal Lost in Spinal Cord of YG8R Mice 
Motor performance impairment could be due to the presence of damaged neurons in the dorsal 
root ganglia and/or spinal cord. Apparently, no changes were observed in the distribution and 
expression of NeuN in the lumbar spinal cord of 8–9-month-old YG8R mice (Figure 2A–C). 
Figure 1. Liver growth factor (L ) tr ll r stores otor c ordination in YG8R mice.
(A) Shows the time (in seconds) spent on the rotating rod at increasing acceleration of the thre groups
of animals observed, demonstrating that under this demanding rotarod co diti n no benefic al effect
of LGF is detected; In (B) th % of times that mice stay on the rotating rod for 3 mi at constant speed
(4 rpm) in th WT (white circles), YG8R (black circles), or YG8R+LGF (grey circles) mic . Note the
poorer performance f YG8R versus WT mice of five to seven months, and that shortly after treatment
values are significantly higher in the LGF-treated t an in the vehicle-treated YG8R mice. Results are
the mean ± Standard Error of Mean (SEM) of 6–8 independent animals. ++ p < 0.01, +++ p < 0.001 vs.
YG8R; * p < 0.05, ** p < 0.01 vs. WT; # p < 0.05, ## p < 0.01 vs. YG8R+LGF.
When we analyzed motor performance at constant speed (4 rpm), we observed that at five to
seven months of age the percentage of times that YG8R mice stayed for three minutes in rotarod was
lower than in WT mice (Figure 1B). At seven to eight months, YG8R+LGF mice showed a significant
increase in this parameter, as compared with YG8R mice (Figure 2B), suggesting that LGF treatment
improved motor coordination in these mice.
2.2. LGF Prevents Neuronal Lost in Spinal Cord of YG8R Mice
Motor performance impairment could be due to the presence of damaged neurons in the
dorsal root ganglia and/or spinal cord. Apparently, no changes were observed in the distribution
and expression of NeuN in the lumbar spinal cord of 8–9-month-old YG8R mice (Figure 2A–C).
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However, the total number of NeuN-positive neurons was significantly reduced in those mice
compared with WT and YG8R+LGF mice (Figure 2D).
We also analyzed NeuN protein expression in the spinal cord, brain stem, and cerebellum.
As shown in Figure 2E, NeuN protein levels were slightly reduced in the spinal cord of YG8R mice,
and LGF treatment significantly increased this parameter above that observed in WT mice. In the brain
stem of YG8R and YG8R+LGF mice NeuN levels were upregulated, as compared with WT mice, while
this protein was not affected in the cerebellum (Figure 2E).
Other studies have described the presence of big vacuoles in the dorsal root ganglia of six-
to 12-month-old YG8R mice [23], but under our experimental conditions we were unable to note
this alteration.
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Figure 2. LGF treatment exerts a neuroprotective effect on neurons of lumbar spinal cord in YG8R 
mice. The upper panel depicts neurons of dorsal horn (black delimited area in (C)) stained for NeuN 
(brown) in the lumbar spinal cord of WT (A), YG8R (B), and YG8R+LGF mice (C); (D) represents the 
quantification of these neurons, revealing a significant reduction of neuronal loss in YG8R mice 
treated with LGF (gray bar) versus YG8R mice treated with vehicle (black bar); (E) shows the effect 
of LGF treatment on NeuN expression, detected by western blot in the spinal cord (SC, red bars), 
cerebellum (CB, blue bars), and brain stem (BS, lilac bars) of YG8R (uniform bars) and YG8R+LGF 
(bars with mesh). Note that LGF significantly increases NeuN expression in spinal cord, whereas it 
has no effect in other brain regions. Lane 1 (WT), Lane 2 (YG8R), Lane 3 (YG8R+LGF). Results are the 
mean ± SEM of three (in the case of the spinal cord) or six (in the rest of structures) independent 
animals. * p < 0.05, ** p < 0.01 vs. WT; + p < 0.05, ++ p <0.01 vs. YG8R. 
Activated microglia are an important source of oxidative stress that could contribute to the 
etiopathology of FA. As shown in Figure 3A–D, a significantly higher number of Iba1-positive 
activated microglia was observed in the spinal cord of YG8R and YG8R+LGF mice, as compared 
with WT mice. Other studies in FA patients have proposed that neuronal degeneration could be due 
to the effect on the Schwann cells and satellite glia. We did not observe any alteration in S-100 
(specific marker of Schwann cells) and Glial Fibrillary Acidic Protein (GFAP) immunoreactivity in 
the dorsal root ganglia of YG8R mice, and GFAP protein expression was not affected in the spinal 
cord of these mice, compared with WT mice (Figure 3E). However, GFAP protein expression was 
raised in the brain stem of YG8R mice, but LGF did not prevent this increase (Figure 1E). 
Figure 2. LGF treatment exerts a neuroprotective effect on neurons of lumbar spinal cord in YG8R
mice. The upper panel depicts neurons of dorsal horn (black delimited area in (C)) stained for NeuN
(brown) in the lumbar spinal cord of WT (A), YG8R (B), and YG8R+LGF mice (C); (D) represents the
quantification of these neurons, revealing a significant reduction of neuronal loss in YG8R mice treated
with LGF (gray bar) versus YG8R mice treated with vehicle (black bar); (E) shows the effect of LGF
treatment on NeuN expression, detected by western blot in the spinal cord (SC, red bars), cerebellum
(CB, blue bars), and brain stem (BS, lilac bars) of YG8R (uniform bars) and YG8R+LGF (bars with
mesh). Note that LGF significantly increases NeuN expression in spinal cord, whereas it has no effect
in other brain regions. Lane 1 (WT), Lane 2 (YG8R), Lane 3 (YG8R+LGF). Results are the mean ± SEM
of three (in the case of the spinal cord) or six (in the rest of structures) independent animals. * p < 0.05,
** p < 0.01 vs. WT; + p < 0.05, ++ p <0.01 vs. YG8R.
Activated microglia are an important source of oxidative stress that could contribute to the
etiopathology of FA. As shown in Figure 3A–D, a significantly higher number of Iba1-positive activated
microglia was observed in the spinal cord of YG8R and YG8R+LGF mice, as compared with WT mice.
Other studies in FA patients have propo ed that neuronal degeneration could be due to the effect
on the S hw nn cells and satellite glia. We did not observe any alteration in S-100 (specific marker
of Schwann cells) and Glial Fibrillary Acidic Protein (GFAP) immunoreactivity in the dor al root
ganglia of YG8R mice, and GFAP protein expression was not aff ct d in the spinal cord of these mice,
compared with WT mice (Figure 3E). However, GFAP prot in expression was raised in the brain stem
of YG8R mice, but LGF did not prevent this increase (Figure 3E).
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Figure 3. Effect of LGF treatment in microglia and Glial Fibrillary Acidic Protein (GFAP) protein 
expression. The upper panel depicts activated microglia stained for Iba1 (brown) in the lumbar 
spinal cord of WT (A), YG8R (B), and YG8R+LGF mice (C); The inset in C shows Iba1-positive cells at 
higher magnification; (D) Represents the quantification of these cells, revealing a significant increase 
in YG8R (black bar) and YG8R+LGF mice (gray bar) versus WT (white bar); (E) Shows the effect of 
LGF treatment on GFAP expression, detected by western blot in the spinal cord (SC, red bars), 
cerebellum (CB, blue bars), and brain stem (BS, lilac bars) of YG8R (uniform bars) and YG8R+LGF 
(bars with mesh). Note how GFAP levels are upregulated in the BS of YG8R and YG8R+LGF mice. 
Lane 1 (WT), Lane 2 (YG8R), Lane 3 (YG8R+LGF). Results are the mean ± SEM of three (in the case of 
the spinal cord) or six (in the rest of structures) independent animals. ** p < 0.01 vs. WT. 
2.3. LGF Treatment Reverses Cardiac Hypertrophy inYG8R Mice 
Cardiac hypertrophy is observed in an important number of FA patients. As shown in Figure 4, 
the diameter of left ventricle cardiomyocytes in YG8R mice was significantly higher than in WT 
mice. This effect was not observed in YG8G+LGF mice, suggesting that LGF treatment reduces 
cardiac hypertrophy in this experimental model of FA. However, LGF treatment did not affect the 
total number of cardiomyocytes in the left ventricle. Thus, no differences were observed in this 
parameter between the different experimental groups of mice analyzed in this study (465 ± 121, 477 ± 
128, 427 ± 108 cardiomyocytes nuclei/mm2 in WT, YG8R and YG8R+LGF mice, respectively. n = 6 
independent mice in each experimental group). 
2.4. LGF Treatment Modulates Frataxin Expression in YG8R Mice 
Frataxin is a mitochondrial protein involved in cellular iron use and maintenance of the redox 
status which expression is reduced in FA. By using an antibody that recognizes human FXN we 
observed that LGF treatment increased FXN protein expression by 1.3- and 1.2-fold in the spinal 
cord and heart of YG8R mice, respectively (Figure 5A). However, no significant changes in FXN 
levels were observed in the cerebellum and brain stem of these mice. 
Ferroportin (FPN) is another protein involved in iron transport that is affected in FA [24].  
FPN protein expression was downregulated in the spinal cord, brain stem, and heart of eight- to 
nine-month-old YGR8 mice, as compared with WT mice, and LGF treatment was unable to recover 
FNP levels to control values in none of these structures (Figure 5B). 
Figure 3. Effect of LGF treatment in microglia and Glial Fibrillary Acidic Protein (GFAP) protein
expression. The upper panel depicts activated microglia stained for Iba1 (brown) in the lumbar spinal
cord of WT (A), YG8R (B), and YG8R+LGF mice (C); The inset in C shows Iba1-positive cells at
higher agnification; (D) Represents the quantification of these cells, revealing a significant increase in
YG8R (black bar) and YG8R+LGF mice (gray bar) versus WT (white bar); (E) Shows the effect of LGF
treatment on GFAP expression, detected by western blot in the spinal cord (SC, red bars), cerebellum
(CB, blue bars), and brain stem (BS, lilac bars) of YG8R (uniform bars) and YG8R+LGF (bars with
mesh). Note how GFAP levels are upregulated in the BS of YG8R and YG8R+LGF mice. Lane 1 (WT),
a e 2 (YG8R), Lane 3 (YG8R+LGF). Results are the mean ± SEM of three (in the case of t e spinal
cord) or six (in the rest of structures) independent animals. ** p < 0.01 vs. WT.
2.3. LGF Treatment Reverses Cardiac Hypertrophy inYG8R Mice
Cardiac hypertrophy is observed in an important number of FA patients. As shown in Figure 4,
the diameter of left ventricle cardiomyocytes in YG8R mice was significantly higher than in WT mice.
This effect was not observed in YG8G+LGF mice, suggesting that LGF treatment reduces cardiac
hypertrophy in this experimental model of FA. However, LGF treatment did not affect the total number
of cardiomyocytes in the left ventricle. Thus, no differences were observed in this parameter between
the different experimental groups of mice analyzed in this study (465 ± 121, 477 ± 128, 427 ± 108
cardiomyocytes nuclei/mm2 in WT, YG8R and YG8R+LGF mice, respectively. n = 6 independent mice
in each experimental group).
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Figure 4. LGF treatment ameliorates cardiac hypertrophy in YG8R mice. (A) to (C) show hematoxylin
(blue) and eosin staining (pink) of left ventricle coronal sections of WT, YG8R, and YG8R+LGF
mice, Scale bar = 15 µm; (D) Represents the quantification of the diameter of cardiomyocytes in the
three experimental groups. Note the increase of this parameter in YG8R mice (black bar), which is
prevented with LGF treatment (gray bar). Results in (D) are the mean± SEM of 360–420 cardiomyocytes
from six independent mice in each experimental group. ** p < 0.01 vs. WT; ++ p < 0.01 vs. YG8R.
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Figure 5. LGF treatment increases frataxin expression in YG8R mice spinal cord. (A) represents the 
effect of LGF on frataxin expression, analyzed by Western blot in the spinal cord (SC, red bars), 
cerebellum (CB, blue bars), brain stem (BS, lilac bars), and heart (green bars) of WT, YG8R (uniform 
bars), and YG8R+LGF (bars with mesh) mice. Note that LGF enhances frataxin expression in the 
spinal cord and heart; In (B) the effect of LGF on ferroportin expression is observed in the same 
structures. Note that the level of this compound is significantly reduced in most structures in YG8R 
mice versus WT mice. Lane 1 (WT), Lane 2 (YG8R), Lane 3 (YG8R+LGF). Results are the mean ± SEM 
of three (in the case of spinal cords) or 6–8 (in the rest of structures) independent animals. * p < 0.05,  
** p < 0.01, *** p < 0.001 vs. WT; + p < 0.05,++ p < 0.01 vs. YG8R. 
LGF treatment increases fr taxin expression in YG8R mice spinal cord. (A) represents
the effect of LGF on frataxin expression, nalyzed by Western blot in the spinal cord (SC, red ),
and YG8R+LGF (bars with mesh) mice. Note that LGF enhances frataxin e pression in the spinal
cord and he rt; In (B) the effec of LGF on ferrop rtin ex ression is ob erved in the same s ructures.
Note that the level of is compound is significantly reduced in most structures in YG8R mice versus
WT mice. Lane 1 (WT), Lane 2 (YG8R), Lane 3 (YG8R+LGF). Results are th mean ± SEM of three (in
the cas of spinal cords) or 6–8 (in the rest of structures) independent animals. * p < 0.05, ** . 1,
*** p < 0.001 vs. WT; + p < 0.05, ++ p < .01 vs. YG8R.
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2.5. Effect of LGF Treatment in the Expression of Proteins Involved in Cell Survival
In our previous studies we proposed that the neuroprotective activity of LGF is mediated by
the regulation of proteins that are critical for cell survival such as Bcl2 and Akt [16,22]. As shown in
Figure 6A, the Bcl-2/Bax ratio was significantly higher in the spinal cord of YG8R than in WT mice.
LGF treatment did not modulate this ratio in this structure, but significantly raised it in the cerebellum
and brain stem (Figure 6A). On the other hand, we observed that the ratio phospho-Akt/Akt was
significantly raised in the spinal cord of YG8R+LGF mice, as compared with WT and YG8R mice.
A similar result was observed in the cerebellum and heart of these mice, but this effect was not
statistically significant in these structures (Figure 6B).
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Stress in YG8R Mice 
Complex IV of the mitochondrial respiratory chain catalyzes the transference of electrons from 
cytochrome C to O2 to produce water. A reduction in its activity was reported in lymphoblasts from 
FA patients [25]. As shown in Figure 7A, complex IV protein levels were significantly reduced in the 
spinal cord and cerebellum of eight-month-old YG8R mice, while this protein was overexpressed in 
their brain stem. LGF treatment restored complex IV levels to control values in the spinal cord 
without affecting the expression of this protein in the other brain structures analyzed (Figure 7A). 
Although cytochrome C levels are also reduced in FA cells [25,26], only the heart of YG8R mice 
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administration of LGF restored cytochrome C levels to control values in the heart, and upregulated 
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Figure 6. LGF treatment increases the expression of molecules involved in cellular survival in several
structures of YG8R mice. (A) The effect of LGF on the ratio of Bcl2/Bax expression, analyzed through
western blot in the spinal cord (SC, red bars), cerebellum (CB, blue bars), brain stem (BS, lilac bars),
and heart (green bars) of WT, YG8R (uniform bars), and YG8R+LGF (bars with mesh) mice. Note that
LGF exerts an anti-apoptotic effect in the cerebellum and brain stem; (B) The effect of LGF on the
ratio of P-Akt/Akt. Note tha LGF treatment s gnificantl ncreases the ratio in he spi al cord and
heart. P-Akt, a m diator in th PI3K/Akt signaling pathway, is essential in the regulation of neuronal
survival. Lane 1 (WT), Lane 2 (YG8R), Lane 3 (YG8R+LGF). Results are the mean ± SEM of three (in
the case of spinal cord) or 6–8 (in the rest of structures) independent animals. * p < 0.05, ** p < 0.01
vs. WT; *** p < 0.001 vs. WT; + p < 0.05, +++ p < 0.001 vs. YG8R.
2.6. LGF Treatment Modulates Cytochrome C and Complex IV Protein Expression and Reduces Oxidative
Stress in YG8R Mice
Complex IV of the mitochondrial respiratory chain catalyzes the transference of electrons from
cytochrome C to O2 to produce water. A reduction in its activity was reported in lymphoblasts from
FA patients [25]. As shown in Figure 7A, co l I protein levels were sig ificantly reduced in
the spinal cord and cereb llum of eight-month-old YG8R mice, while this protein was overexpressed
in their brain stem. LGF treatment rest red complex IV levels to c trol values in the spinal cord
without affecting the expression of this protein in the other brain structures analyzed (Figure 7A).
Although cytochrome C levels are also reduced in FA cells [25,26], only the heart of YG8R mice showed
a significant decrease in its expression, as compared with WT mice (Figure 7B). The administration of
LGF restored cytochrome C levels to control values in the heart, and upregulated its expression in the
spinal cord, cerebellum, and brain stem (Figure 7B).
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Figure 7. LGF treatment modulates Complex IV and cytochrome C expression in YG8R mice.
(A) The effect of LGF on Complex IV (CIV) expression, analyzed by western blot in the spinal cord
(SC, red bars), cerebellum (CB, blue bars), brain stem (BS, lilac bars), and heart (green bars) of WT,
YG8R (uniform bars), and YG8R+LGF (bars with mesh) mice. Note that the level of this compound is
significantly reduced in the spinal cord and cerebellum in YG8R mice versus WT mice, and LGF only
reverses CIV reduction in the spinal cord; In (B) the effect of LGF on cytochrome C is observed in the
same structures. Note how cytochrome C expression is reduced in the heart of YG8R mice, and how
LGF treatment increases its levels in all the structures analyzed. Lane 1 (WT), Lane 2 (YG8R), Lane 3
(YG8R+LGF). Results are the ean ± SEM of three (in the case of spinal cords) or 6–8 (in the rest of
structures) independent animals. * p < 0.05, ** p < 0.01 vs. WT; + p < 0.05 vs. YG8R.
Glutathione is the most abundant non-enzymatic antioxidant in cells [27] and its oxidized form is
increased in FA [25,28]. In the skeletal muscle of YG8R mice, the ratio of oxidized glutathione (GSSH)
to reduced glutathione (GSH) was upregulated. LGF treatment reduced this parameter to the values
observed in WT mice (Figure 8). This effect was due to the increase in GSH promoted by the factor
in this structure (313 ± 54, 263 ± 46, +449 ± 69 ng/g of tissue in WT, YG8R and YG8R+LGF mice,
respectively. + p < 0.05 vs. YG8R, n = 6 independent mice in each experimental group).
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Figure 8. LGF treatment decreases oxidative stress in YG8R mice skeletal muscle. The figure represents
the ratio of oxidized glutathione (GSSG) to reduced glutathione (GSH) in the skeletal muscle of WT
(white bar), YG8R (black bar), and YG8R+LGF (gray bar) mice. Note that the ratio is significantly
increased in YG8R mice versus WT mice, while LGF treatment restores this alteration. esults are the
mean ± SEM of 6–8 independent animals. * p < 0.05 vs. WT; ++ p < 0.01 vs. YG8R.
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3. Discussion
In the experimental model of FA used in this study (YG8R mouse), LGF treatment prevented
neuronal loss and reduction of Complex IV expression in association with an increase in Frataxin and
in P-Akt/Akt ratio in the spinal cord; it increased Bcl2/Bax ratio in the brain stem and cerebellum;
it reduced hypertrophy in the heart; and it reduced the ratio of oxidized glutathione versus reduced
glutathione in skeletal muscle. LGF’s beneficial effects correlate with a partial restoration of motor
coordination in YG8R+LGF mice.
The YG8R transgenic mice is considered a good model of FA that shows a similar, but milder,
neuropathology to that presented in FA patients [23]. Thus, the presence of big vacuoles in the neurons
of the dorsal root ganglia of the lumbar spinal cord of these mice clearly indicates their degeneration.
Although we were unable to detect these vacuoles at any of the different levels of the spinal cord
analyzed (lumbar, thoracic, and cervical), we observed an important reduction in the number of
NeuN-positive neurons in the spinal cord of eight-month-old YG8R. To our knowledge, this is the
first study that shows neuronal depletion in YG8R mice, especially in an area (lumbar spinal cord
dorsal horn) where the sensitive neurons that project to the cerebellum through the spinocerebellar
tract, and that are affected in FA, are located [29]. According to several studies in FA patients, neuronal
degeneration could be due to the affectation of the Schwann cells and satellite glia [30,31]. We did not
observe any alteration in S-100 and GFAP immunoreactivity in the dorsal root ganglia of YG8R mice,
and GFAP protein expression was not affected in the spinal cord of these mice, compared with WT
mice. However, in this latter structure the presence of Iba1-positive activated microglia was increased
by 1.7-fold, suggesting that chronic inflammation could be responsible for the reduction of neurons
observed in the spinal cord of YG8R.
Neuronal loss was not observed in the lumbar spinal cord of YG8R+LGF mice, and LGF treatment
upregulated NeuN protein expression in this structure. Apparently, this neuroprotective effect was not
due to a reduction in microglia Iba1-positive, but we cannot exclude a potential anti-inflammatory effect
due to the factor. In fact, long-term LGF treatment reduced the expression of some proinflammatory
associated proteins (TNF-α and OX6) in hemiparkinsonian and ataxic rats [16,22]. On the other hand,
in an experimental model of CA we reported that LGF neuroprotection could be mediated through the
modulation of the anti-apoptotic protein Bcl2 [22]. As shown here, LGF treatment did not modulate
the Bcl2/Bax ratio in the spinal cord of YG8R mice, suggesting that the overexpression of Bcl2 does
not mediate the neuroprotective effect of LGF observed in this structure. However, our results
suggest that LGF could modulate the activity of the PI3K/Akt signaling pathway, because the ratio
phospho-Akt/Akt was upregulated in the spinal cord of IG8R+LGF mice. This signaling pathway
plays a critical role in the regulation of neuronal survival, and, as reported in an experimental model of
Parkinson´s disease [16], it could be partially involved in the neuroprotective activity of LGF observed
in this study. Our results also show that LGF upregulates Bcl2/Bax ratio in the cerebellum and brain
stem of YG8R mice, indicating a potential neuroprotective effect of the factor in these brain structures
that are affected in FA patients.
Hypertrophic cardiomyopathy is the first cause of mortality in FA patients. Their heart is
enlarged and shows interstitial cardiomyopathy, necrosis, and granular degeneration and hypertrophy
of fibers [32,33]. Several alterations associated with cardiac hypertrophy have been described in
YG8R mice [23]. Here, we show that the size of the left ventricle cardiomyocytes was significantly
higher in eight-month-old YG8R than in WT mice. Because the number of cardiomyocytes was
similar in both experimental groups, these results are indicative of cardiac hypertrophy in the YG8R
mice. In an experimental model of hypertension, chronic administration of LGF improved vascular
function [14] and ventricular hypertrophy [10]. Interestingly, in the YG8R mice LGF treatment reduced
the size of the cardiomyocytes to a value similar to that observed in WT mice, suggesting that LGF
treatment prevents cardiac hypertrophy in this experimental model of FA.
The pathophysiology of FA is due to the reduced amount of frataxin in targeted neural and
non-neural cells and tissues. Under our experimental conditions, LGF treatment upregulated frataxin
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protein levels in the spinal cord and heart of eight- to nine-month-old YG8R mice. In the case of the
heart, this increase was significant but very mild. Perhaps this increase would be more evident if we
had analyzed the mitochondrial fraction, but we did not perform a subcellular fractionation in this
study due to the small amount of tissue obtained from each mouse. The mechanism used by LGF to
potentiate frataxin expression is unknown at present, but previous studies pointed out its ability to
potentiate protein synthesis in the damaged liver [34]. In addition, LGF is a potent antioxidant [20,35],
and a recent report demonstrated that IGF-I also has antioxidant activity and stimulates frataxin
expression in neurons and astrocytes deficient of this protein through the Akt/mTOR signaling
pathway [36]. As mentioned above, LGF significantly increases the phospho-Akt/Akt ratio in the
spinal cord. In the heart of YG8R+LGF mice this ratio was raised by 1.5-fold, so we may suggest that
Akt could also participate in the upregulation of frataxin reported in our study.
A recent study has proposed that in FA iron overload could be more cytosolic than
mitochondrial [37]. This overload could be due to an increase in iron uptake, or a reduction in its
release through cytosolic transporters such as ferroportin. To our knowledge, this is the first study that
shows a decrease in ferroportin protein levels in the spinal cord, brain stem, and heart of YG8R mice,
which is consistent with the reduction in ferroportin immunoreactivity reported in FA patients [30].
LGF treatment did not prevent this reduction, suggesting that this factor is unable to reverse the cell
toxicity induced by cytosolic iron overload in these structures.
Reduced levels of frataxin induce deregulation in the activity of I, II, and III mitochondrial
chain complexes [2,38–40]. Other studies also described disturbances in complex IV activity in
frataxin-deficient cells and lymphoblasts of FA patients [25,41]. Here, we report a reduction in complex
IV protein expression in the spinal cord and cerebellum of YG8R mice. Because this mitochondrial
complex catalyzes the transference of electrons from cytochrome C to O2 to produce water, its reduction
could promote an inadequate transfer of electrons from complex III, and an increase in free radicals that
probably induces cellular damage. LGF treatment restored complex IV levels and raised cytochrome
C protein expression in the spinal cord. The upregulation of both proteins could favor a reduction
in the concentration of free radicals in neurons, which could explain the beneficial effects observed
in this study. In the cerebellum LGF was unable to upregulate complex IV expression, but increased
cytochrome C levels, suggesting a potential compensatory mechanism induced by the factor to regulate
complex IV activity in this structure. We should mention that complex IV levels were significantly
increased in the brain stem of YG8R mice, and LGF did not modulate its expression. Similar results
were observed in NeuN and GFAP levels, so we may consider that the overexpression in this structure
of these three proteins is not a previously reported characteristic of the YG8R mice. As observed
in the spinal cord and cerebellum, LGF treatment raised cytochrome C expression, suggesting a
potential neuroprotective activity of the factor in the brain stem. The heart of the YG8R mice showed a
significant decrease in cytochrome C levels that could be involved in a reduction of complex IV activity.
LGF probably compensates for the lack of activity in this structure by preventing the reduction in
cytochrome C levels, as observed in the heart of YG8R+LGF mice.
Dysregulation of glutathione homeostasis and alterations in glutathione-dependent enzyme
activities contributes to the initiation and progression of neurodegenerative diseases including FA [42].
Here we show that the ratio GSSH/GSH was upregulated in the skeletal muscle of YG8R mice,
indicating an increase in oxidative stress that, as reported in FA [43], may contribute to cell damage
in this structure. A similar result was observed in the dorsal root ganglia of these mice [28], and in
frataxin-depleted cells where impairment of glutathione homeostasis and changes in glutathionylation
and function of specific proteins were found [25,28,41,44–46]. A previous study shows the ability of
LGF to reduce oxidative stress in the cardiovascular system of hypertensive rats [21]. We also found a
reduction in this parameter because upregulation of the GSSH/GSH ratio was not observed in the
skeletal muscle of YG8R+LGF mice. This positive effect was due to an increase in the reduced form of
glutathione (GSH) that is critical for protecting tissues from oxidative stress, acting as a free radical
scavenger and inhibitor of lipid peroxidation. On the other hand, LGF administration could reduce
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oxidative stress through the upregulation of the nuclear factor erythroid 2-related factor 2 (Nrf2), as
reported in an experimental model of cigarette smoke-induced emphysema [47]. This transcription
factor, which is defective in FA patients [43], restores redox homeostasis in the cell by inducing the
expression of antioxidant enzymes. Further experiments must be conducted to determine if LGF
modulates Nrf2 expression in YG8R and in frataxin-deficient cells obtained from FA patients.
We evaluated the effectiveness of LGF treatment in motor coordination as analyzed by the
rotarod. As mentioned above, the YG8R mice partially reproduce the human symptoms of FA.
Between three and six months of age, these mice show mild motor coordination failures and a
decreased motor activity, and develop ataxia at 24 months [23]. In our hands, failures in motor
coordination were only detected at five to seven months in YG8R mice due to the impairment in
this parameter observed in eight-month-old WT mice. LGF treatment did not ameliorate motor
coordination in accelerating rotarod test. However, at a constant speed (4 rpm) the percentage of times
that seven- to eight-month-old YG8R+LGF mice stayed in the rotarod for more than 3 min was higher
than in YG8R mice. Perhaps the lack of effect observed in the accelerating test could be due to the
demanding parameters used in our study (4 to 40 rpm in 1 min). In fact, other authors had to change
their protocol in order to detect an improvement in motor coordination of YG8R mice treated with
IGF-I [36]. Thus, although our results suggest that LGF ameliorates motor coordination in YG8R mice,
the effectiveness of the factor has to be ascertained by using other parameters in the acceleration test
such as those described for IGF-I (4 to 40 rpm in 3 to 5 min).
Finally, from our results we are not able to define if the effects of LGF observed here are due to
direct or indirect action of the growth factor on the affected nervous tissue. A direct action would
imply that LGF could cross the blood–brain barrier through several mechanisms involved in the
transendothelial transport of albumin and albumin-conjugated nutrients [48,49]. Alternatively, LGF
could bind to specific receptors present in the blood–brain barrier. The receptors for the advanced
glycation end products (RAGE) located in the endothelium could be good candidates, since AGE
products have similar biochemical properties to LGF, i.e., they are mostly albumins bound to glucose,
which changes albumin conformation [50]. Moreover, RAGE stimulation elicits the release of TNF-α,
which is a cytokine that participates in LGF-mediated proliferation and neuroregeneration [15].
4. Experimental Section
4.1. LGF Purification
LGF was obtained with the highest purity from rat serum following a previously reported
procedure [11]. The absence of contaminants and/or other growth factors (purity) in the LGF
preparation was also evaluated following the standard criteria described by Díaz-Gil et al. [7–9,11].
All LGF preparations showed a single band in SDS-PAGE electrophoresis and were lyophilized and
kept at 4 ◦C until use. Finally, LGF aliquots were dissolved in saline prior to administration.
4.2. Ethics Statement
The Ethics Committee of the Hospital Ramón y Cajal, Madrid (animal facilities ES280790002001)
approved all the protocols related to the use of laboratory animals. All procedures associated with
animal experiments were in accordance with Spanish legislation (RD 53/2013) and the European
Union Council Directive (2010/63/EU).
4.3. Experimental Model of Friedreich’s Ataxia in Mice
Twelve two- to three-month-old male Fxn tm1Mkn/Tg(FXN)YG8Pook (YG8R) mice were obtained
from the Jackson Laboratory (Bar Harbor, ME, USA), and used in accordance with the European Union
Council Directive (86/609/EEC). These mice are homozygous for the Fxntm1Mkn (frataxin) targeted
allele and hemizygous for the Tg(FXN)YG8Pook (frataxin, human) transgene, and show a similar, but
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milder, neuropathology to that presented in FA patients [23]. As wild-type mice (WT) we used the
C57BL/6J strain that was grown in our animal facilities.
4.4. Behavioral Testing
Motor performance was analyzed using the rotarod test (PanLab S.L., Mod. LE 8500, Cornellá,
Spain). Briefly, mice received four 3-min evaluations at 4 rpm (constant speed), and four 1-min
evaluations at 4 to 40 rpm (accelerating rod) once a month, starting at three months of age until
the end of the study period. Data at constant speed were expressed as the percentage of times that
mice stayed for 3 min on the rotarod at 4 rpm. This percentage was obtained from four independent
evaluations/mouse at each experimental time analyzed in this study.
4.5. LGF Administration
At six months of age, mice received two weekly IP injections of saline (YG8R, n = 6) or LGF
(1.7 µg/mice) (YGR+LGF, n = 6) for three weeks. This optimal dose of LGF has been used in different
model systems using an identical or similar schedule. Mice were sacrificed four weeks after the last
treatment with vehicle or LGF. A total of six WT mice were also used as controls.
4.6. Tissue Processing
Eight-month-old mice were beheaded under deep anesthesia with isoflurane, and their brain
stems, cerebellums, and spinal cords were removed and dissected following a previously described
methodology [51]. For histological studies, the spinal cord was isolated from the vertebral column,
fixed in 4% paraformaldehyde for four days, and included in HCl + EDTA for 2 h. After several
washings the spinal cords were dehydrated and included in paraffin. For histological studies, and
since we were interested in analyzing dorsal root ganglia and fibers and ventral root fibers, spinal cords
were maintained within their vertebral columns during fixation in 4% paraformaldehyde for four days,
and were coronally cut into three pieces corresponding to the cervical, thoracic, and lumbar-sacral
cord. Afterwards, vertebral columns were decalcified through treatment with HCl + EDTA for 2 h and,
after several washings, spinal cord pieces were dehydrated and included in paraffin.
4.7. Antibodies and Immunochemicals (Histology)
The primary antibodies used in this study were: mouse anti-neuronal nuclei (NeuN, 1:1000;
Chemicon International Inc., Temecula, CA, USA), mouse anti-frataxin (1:100; Millipore Ibérica
S.A.U., Madrid, Spain), and mouse anti-Iba1 (1:300; Wako Chemicals GmbH, Neuss, Germany).
The immunochemicals and secondary antibodies that were used in histology are listed below: Alexa
Fluor-568 goat anti-mouse IgG, and Alexa Fluor-488 goat anti-rabbit IgG (1:400; all from Molecular
Probes; Eugene, OR, USA), diaminobenzidine (DAB) + substrate-chromogen system (both from Dako
Cytomation, Carpinteria, CA, USA), streptavidin–biotin–peroxidase complex (Dako Cytomation) and
biotinylated goat anti-mouse IgG (Zymed Laboratories, San Francisco, CA, USA).
4.8. Immunohistochemistry and Morphometric Analysis
For pathological and immunohistochemical analyses of the spinal cord, 8 µm thick coronal sections
from the three medullar levels (lumbar, thoracic, and cervical) were obtained in a microtome (Microm,
Mod. HM 325, Walldorf, Germany), and mounted in positive charged slides (DakoCytomation,
Copenhagen, Denmark). Tissue sections were treated with sodium acetate 10 mM, pH 6.0, at 95 ◦C for
4 min, and preincubated with 5% normal goat serum (NGS) in Tris-buffered saline (TBS: 0.15 M NaCl
and 0.1 M Tris HCl, pH 7.4)/0.1% Triton X-100 for 30 min. Primary antibodies were applied for
24 h at 4 ◦C, and most of them were visualized using immunofluorescence procedures. The slides
were coverslipped in a medium containing p-phenylenediamine and bisbenzimide (Hoechst 33342;
Sigma Aldrich, St. Louis, MO, USA) for detection of nuclei.
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For pathological studies, sections stained for hematoxylin and eosin from each spinal cord piece
(cervical, thoracic, and lumbar) were selected, so that per piece at least two to three dorsal root ganglia
and their corresponding spinal cord section were analyzed.
For quantitative estimation of NeuN and Iba1 immunostaining, sections were selected from spinal
cord levels where the ventral horn had the widest extension: C6 and C7 of cervical cord pieces, T3 of
thoracic cord pieces, and L4 of lumbar cord pieces. The number of immunoreactive cells was quantified
in the whole surface of spinal cord grey matter (including both dorsal and ventral horns), which was
visualized through images from stitched widefields of each side of the spinal cord, using the 20× lens
and Nikon NIS elements software (scan large image function, Nikon, Tokyo, Japan), connected to a
Nikon ECLIPSE Ti-e microscope (Nikon), equipped with a Nikon DS-2MV camera. The quantitative
estimation was expressed as the number of immunoreactive cells per mm2.
4.9. Heart Histological Analysis
For histological studies, ventricular tissues were fixed in 4% buffered formalin and embedded
in paraffin wax. Tissues were sectioned at 5 µm and stained with hematoxylin-eosin, Masson’s
trychrome, and periodic acid–Schiff stain (PAS). Coronal sections of ventricular tissue were taken.
Due to randomized histological cut sections stained with Masson’s trychrome, the first subvalvular
coronal sample were measured on a millimeter scale (KODAK RFS 3570 Film Scanner, Flubacher + Co.,
F+C). Data were expressed as surface of muscular ventricular heart per millimeter (mm) of epicardial
layer, because all histological sections are not always at exactly the same height and ventricular cavities
are different in each sample. The cardiomyocyte size of the left ventricle was measured through
photographs of three high-power fields (objective ×40). The minor diameter of cardiomyocytes was
measured. Those with a diameter lower than 16 micrometers were rejected for consideration as a
dichotomy branch of cells; and those with a diameter higher than 36 micrometers were also rejected
because the borders between cardiomyocytes were not well delimited.
4.10. Western Blotting Protein Analysis
Heart and brain tissue samples were homogenized (1:8 (w/v)) using lysis buffer (20 mM Tris-HCl,
pH 7.5: 1 mM dithiothreitol, 2 mM benzamidine,0.5% Triton X-100, 10 µg/mL pepstatin A, 140 mM
potassium chloride; 5 mM magnesium acetate; 1 mM EDTA, 2 mM EGTA, 10 µg/mL leupeptin
20 mM sodium β-glycerophosphate; 20 mM sodium molybdate, 200 mM sodium orthovanadate,
10 µg/mL antipain, and 2 mM EGTA) and then were centrifuged at 11,000× g for 20 min.
All procedures were performed at 4 ◦C. Samples were aliquoted and then kept at −80 ◦C until
used. Protein concentrations were determined for each sample. Samples containing 30 µg of protein
were analyzed by SDS-PAGE and transferred onto PVDF membranes (GE Healthcare, Barcelona,
Spain). Membranes were blocked with 0.1 M PBS and 5% dry skimmed milk, pH 7.4, and incubated
overnight at 4 ◦C with the primary antibodies mouse anti-NeuN (1:1000; Chemicon International Inc.,
Temecula, CA, USA), rabbit anti-Akt (Ser473P) (1:2000, Cell Signaling Technology, Beverly, MA, USA),
rabbit anti-Akt (1:2000, Cell Signaling Technology), rabbit anti-ferroportin (1:1000, Bioss Chemicals,
Pamiers, France), mouse anti-frataxin (1:1000, Millipore, Temecula, CA, USA), mouse anti-complex
IV (1:1000, Invitrogen, Carlsbad, CA, USA), mouse anti-cytochrome C (1:1000, BD Pharmigen,
Haryana, India), and rabbit anti-GFAP (1:500; Dako Cytomation, Denmark), mouse anti-Bcl-2
(1:400; Santa Cruz Biotechnology Inc., Burlingame, CA, USA) and rabbit anti-Bax (1:300; Santa
Cruz Biotechnology Inc.). After extensive washing in 0.05% PBS-Tween, membranes were incubated
with the peroxidase-conjugated or alkaline-phosphatase-conjugated secondary antibodies diluted
1:2000 in blocking solution. The membranes were developed with enhanced chemiluminescence
Western blotting, following the manufacturer’s instructions (Amersham, Buckinghamshire, UK), and
were exposed to hyperfilm. Membranes were also immunolabeled for loading control using mouse
anti-β actin (1:5000; Sigma Aldrich) or mouse anti-GAPDH (1:5000; Sigma Aldrich) and anti-mouse
IgG alkaline phosphatase-conjugated (1:3000, Sigma Aldrich) and were developed with alkaline
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phosphatase reagent. The density of the stained bands was scanned and quantified with the Image
QuantTL software package (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and the data were
normalized in relation to β actin or GAPDH levels.
4.11. Glutathione Determination
Total GSH levels were measured following the method described by Tietze [52]. Briefly, tissue from
skeletal muscle was lysed in 100 µL of 0.4 N perchloric acid (PCA) for 30 min at 4 ◦C, and centrifuged.
The supernatants were neutralized with four volumes of 0.1 M NaH2PO4, 5 mM EDTA, pH 7.5. GSH
content was measured in a p96 automatic reader by the addition of 5,5-dithio-bis-2-nitrobenzoic acid
(DTNB, 0.6 mM), nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt (NADPH,
0.2 mM), and glutathione reductase (1 U). The reaction was monitored at 412 nm for 6 min.
4.12. Data Analysis
Results are expressed as mean ± Standard Error of Mean (SEM) of (n) independent animals.
Statistical analyses for immunohistochemical and biochemical studies were performed using one-way
ANOVA followed by the Newman–Keuls multiple comparison test. For behavioral studies, a two-way
ANOVA followed by Newman–Keuls multiple comparison test was used. Differences were considered
significant when p ≤ 0.05.
5. Conclusions
1. Among the regions of the central nervous system of eight-month-old YG8R mice analyzed
in the present study, the spinal cord displays the most alterations in the parameters evaluated
here. This structure shows a significant decrease in the number of neurons in the lumbar region,
and in the expression of ferroportin and Complex IV (cytochrome oxidase), while the number of
microglia increases.
2. Abnormalities found in other regions include a decrease in Complex IV in cerebellum,
hypertrophy in cardiomyocytes, a decrease in ferroportin in the heart, and an increase in the ratio of
oxidized glutathione versus reduced glutathione in skeletal muscle.
3. These pathologic changes correlate with the impairment in motor coordination observed in
five- to seven-month-old YG8R mice, as compared with WT mice.
4. LGF treatment ameliorates the pathology of YG8R mice through the neurotrophic, antioxidant,
and antiapoptotic activities of the factor, and the induction of neuronal and mitochondrial protein
expression. Thus, LGF prevents neuronal loss and reduction of Complex IV expression in association
with an increase in Frataxin and in the P-Akt/Akt ratio in the spinal cord; it increases Bcl2/Bax ratio
in the brain stem and cerebellum; it reduces hypertrophy and increases Frataxin in the heart; and it
reduces the ratio of oxidized glutathione to reduced glutathione in skeletal muscle.
5. LGF’s beneficial effects correlate with a partial restoration of motor coordination in YG8R+LGF
mice, detectable as a significant increase in the percentage of times that mice stayed for 3 min on the
rotating rod at constant speed.
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